Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Frederic Rousseau is active.

Publication


Featured researches published by Frederic Rousseau.


Nature Biotechnology | 2004

Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins.

Ana-Maria Fernandez-Escamilla; Frederic Rousseau; Joost Schymkowitz; Luis Serrano

We have developed a statistical mechanics algorithm, TANGO, to predict protein aggregation. TANGO is based on the physico-chemical principles of β-sheet formation, extended by the assumption that the core regions of an aggregate are fully buried. Our algorithm accurately predicts the aggregation of a data set of 179 peptides compiled from the literature as well as of a new set of 71 peptides derived from human disease-related proteins, including prion protein, lysozyme and β2-microglobulin. TANGO also correctly predicts pathogenic as well as protective mutations of the Alzheimer β-peptide, human lysozyme and transthyretin, and discriminates between β-sheet propensity and aggregation. Our results confirm the model of intermolecular β-sheet formation as a widespread underlying mechanism of protein aggregation. Furthermore, the algorithm opens the door to a fully automated, sequence-based design strategy to improve the aggregation properties of proteins of scientific or industrial interest.


The EMBO Journal | 2010

Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio

Inna Kuperstein; Kerensa Broersen; Iryna Benilova; Jef Rozenski; Wim Jonckheere; Maja Debulpaep; Annelies Vandersteen; Ine Segers-Nolten; Kees van der Werf; Vinod Subramaniam; Dries Braeken; Geert Callewaert; Carmen Bartic; Rudi D'Hooge; Ivo Martins; Frederic Rousseau; Joost Schymkowitz; Bart De Strooper

The amyloid peptides Aβ40 and Aβ42 of Alzheimers disease are thought to contribute differentially to the disease process. Although Aβ42 seems more pathogenic than Aβ40, the reason for this is not well understood. We show here that small alterations in the Aβ42:Aβ40 ratio dramatically affect the biophysical and biological properties of the Aβ mixtures reflected in their aggregation kinetics, the morphology of the resulting amyloid fibrils and synaptic function tested in vitro and in vivo. A minor increase in the Aβ42:Aβ40 ratio stabilizes toxic oligomeric species with intermediate conformations. The initial toxic impact of these Aβ species is synaptic in nature, but this can spread into the cells leading to neuronal cell death. The fact that the relative ratio of Aβ peptides is more crucial than the absolute amounts of peptides for the induction of neurotoxic conformations has important implications for anti‐amyloid therapy. Our work also suggests the dynamic nature of the equilibrium between toxic and non‐toxic intermediates.


The EMBO Journal | 2008

Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice

Ivo Cristiano Martins; Inna Kuperstein; Hannah Wilkinson; Elke Maes; Mieke Vanbrabant; Wim Jonckheere; Patrick Van Gelder; Dieter Hartmann; Rudi D'Hooge; Bart De Strooper; Joost Schymkowitz; Frederic Rousseau

Although soluble oligomeric and protofibrillar assemblies of Aβ‐amyloid peptide cause synaptotoxicity and potentially contribute to Alzheimers disease (AD), the role of mature Aβ‐fibrils in the amyloid plaques remains controversial. A widely held view in the field suggests that the fibrillization reaction proceeds ‘forward’ in a near‐irreversible manner from the monomeric Aβ peptide through toxic protofibrillar intermediates, which subsequently mature into biologically inert amyloid fibrils that are found in plaques. Here, we show that natural lipids destabilize and rapidly resolubilize mature Aβ amyloid fibers. Interestingly, the equilibrium is not reversed toward monomeric Aβ but rather toward soluble amyloid protofibrils. We characterized these ‘backward’ Aβ protofibrils generated from mature Aβ fibers and compared them with previously identified ‘forward’ Aβ protofibrils obtained from the aggregation of fresh Aβ monomers. We find that backward protofibrils are biochemically and biophysically very similar to forward protofibrils: they consist of a wide range of molecular masses, are toxic to primary neurons and cause memory impairment and tau phosphorylation in mouse. In addition, they diffuse rapidly through the brain into areas relevant to AD. Our findings imply that amyloid plaques are potentially major sources of soluble toxic Aβ‐aggregates that could readily be activated by exposure to biological lipids.


Nature Chemical Biology | 2011

Gain of function of mutant p53 by coaggregation with multiple tumor suppressors

Jie Xu; Joke Reumers; José Couceiro; Frederik De Smet; Rodrigo Gallardo; Stanislav Rudyak; Ann Cornelis; Jef Rozenski; Aleksandra Zwolinska; Jean-Christophe Marine; Diether Lambrechts; Young-Ah Suh; Frederic Rousseau; Joost Schymkowitz

Many p53 missense mutations possess dominant-negative activity and oncogenic gain of function. We report that for structurally destabilized p53 mutants, these effects result from mutant-induced coaggregation of wild-type p53 and its paralogs p63 and p73, thereby also inducing a heat-shock response. Aggregation of mutant p53 resulted from self-assembly of a conserved aggregation-nucleating sequence within the hydrophobic core of the DNA-binding domain, which becomes exposed after mutation. Suppressing the aggregation propensity of this sequence by mutagenesis abrogated gain of function and restored activity of wild-type p53 and its paralogs. In the p53 germline mutation database, tumors carrying aggregation-prone p53 mutations have a significantly lower frequency of wild-type allele loss as compared to tumors harboring nonaggregating mutations, suggesting a difference in clonal selection of aggregating mutants. Overall, our study reveals a novel disease mechanism for mutant p53 gain of function and suggests that, at least in some respects, cancer could be considered an aggregation-associated disease.


Nucleic Acids Research | 2006

PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes

Lucía Conde; Juan M. Vaquerizas; Hernán Dopazo; Leonardo Arbiza; Joke Reumers; Frederic Rousseau; Joost Schymkowitz; Joaquín Dopazo

We have developed a web tool, PupaSuite, for the selection of single nucleotide polymorphisms (SNPs) with potential phenotypic effect, specifically oriented to help in the design of large-scale genotyping projects. PupaSuite uses a collection of data on SNPs from heterogeneous sources and a large number of pre-calculated predictions to offer a flexible and intuitive interface for selecting an optimal set of SNPs. It improves the functionality of PupaSNP and PupasView programs and implements new facilities such as the analysis of users data to derive haplotypes with functional information. A new estimator of putative effect of polymorphisms has been included that uses evolutionary information. Also SNPeffect database predictions have been included. The PupaSuite web interface is accessible through and through .


Bioinformatics | 2011

A graphical interface for the FoldX forcefield

Joost Van Durme; Javier Delgado; Francois Stricher; Luis Serrano; Joost Schymkowitz; Frederic Rousseau

SUMMARYnA graphical user interface for the FoldX protein design program has been developed as a plugin for the YASARA molecular graphics suite. The most prominent FoldX commands such as free energy difference upon mutagenesis and interaction energy calculations can now be run entirely via a windowed menu system and the results are immediately shown on screen.nnnAVAILABILITY AND IMPLEMENTATIONnThe plugin is written in Python and is freely available for download at http://foldxyasara.switchlab.org/ and supported on Linux, MacOSX and MS Windows.


Nucleic Acids Research | 2012

SNPeffect 4.0: on-line prediction of molecular and structural effects of protein-coding variants

Greet De Baets; Joost Van Durme; Joke Reumers; Sebastian Maurer-Stroh; Peter Vanhee; Joaquín Dopazo; Joost Schymkowitz; Frederic Rousseau

Single nucleotide variants (SNVs) are, together with copy number variation, the primary source of variation in the human genome and are associated with phenotypic variation such as altered response to drug treatment and susceptibility to disease. Linking structural effects of non-synonymous SNVs to functional outcomes is a major issue in structural bioinformatics. The SNPeffect database (http://snpeffect.switchlab.org) uses sequence- and structure-based bioinformatics tools to predict the effect of protein-coding SNVs on the structural phenotype of proteins. It integrates aggregation prediction (TANGO), amyloid prediction (WALTZ), chaperone-binding prediction (LIMBO) and protein stability analysis (FoldX) for structural phenotyping. Additionally, SNPeffect holds information on affected catalytic sites and a number of post-translational modifications. The database contains all known human protein variants from UniProt, but users can now also submit custom protein variants for a SNPeffect analysis, including automated structure modeling. The new meta-analysis application allows plotting correlations between phenotypic features for a user-selected set of variants.


Neurology | 2008

Progranulin genetic variability contributes to amyotrophic lateral sclerosis.

K Sleegers; Nathalie Brouwers; Sebastian Maurer-Stroh; M. A. van Es; P. Van Damme; P.W.J. van Vught; J. van der Zee; Sally Serneels; T. De Pooter; M Van den Broeck; Marc Cruts; Joost Schymkowitz; P. De Jonghe; Frederic Rousseau; L. H. van den Berg; Wim Robberecht; C. Van Broeckhoven

Objectives: Null mutations in progranulin (PGRN) cause ubiquitin-positive frontotemporal dementia (FTD) linked to chromosome 17q21 (FTDU-17). Here we examined PGRN genetic variability in amyotrophic lateral sclerosis (ALS), a neurodegenerative motor neuron disease that overlaps with FTD at a clinical, pathologic, and epidemiologic level. Methods: We sequenced all exons, exon-intron boundaries, and 5′ and 3′ regulatory regions of PGRN in a Belgian sample of 230 patients with ALS. The frequency of observed genetic variants was determined in 436 healthy control individuals. The contribution of eight frequent polymorphisms to ALS risk, onset age, and survival was assessed in an association study in the Belgian sample and a replication series of 308 Dutch patients with ALS and 345 Dutch controls. Results: In patients with ALS we identified 11 mutations, 5 of which were predicted to affect PGRN protein sequence or levels (four missense mutations and one 5′ regulatory variant). Moreover, common variants (rs9897526, rs34424835, and rs850713) and haplotypes were significantly associated with a reduction in age at onset and a shorter survival after onset of ALS in both the Belgian and the Dutch studies. Conclusion: PGRN acts as a modifier of the course of disease in patients with amyotrophic lateral sclerosis, through earlier onset and shorter survival.


Alzheimer's Research & Therapy | 2010

The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

Kerensa Broersen; Frederic Rousseau; Joost Schymkowitz

Since the reformulation of the amyloid cascade hypothesis to focus on oligomeric aggregates of amyloid beta as the prime toxic species causing Alzheimers disease, many researchers refocused on detecting a specific molecular assembly of defined size thatis the main trigger of Alzheimers disease. The result has been the identification of a host of molecular assemblies containing from two up to a hundred molecules of the amyloid beta peptide, which were all found to impair memory formation in mice. This clearly demonstrates that size is insufficient to define toxicity and peptide conformation has to be taken into account. In this review we discuss the interplay between oligomer size and peptide conformation as the key determinants of the neurotoxicity of the amyloid beta peptide.


Molecular & Cellular Proteomics | 2011

Redox Proteomics of Protein-bound Methionine Oxidation

Bart Ghesquière; Veronique Jonckheere; Niklaas Colaert; Joost Van Durme; Evy Timmerman; Marc Goethals; Joost Schymkowitz; Frederic Rousseau; Joël Vandekerckhove; Kris Gevaert

We here present a new method to measure the degree of protein-bound methionine sulfoxide formation at a proteome-wide scale. In human Jurkat cells that were stressed with hydrogen peroxide, over 2000 oxidation-sensitive methionines in more than 1600 different proteins were mapped and their extent of oxidation was quantified. Meta-analysis of the sequences surrounding the oxidized methionine residues revealed a high preference for neighboring polar residues. Using synthetic methionine sulfoxide containing peptides designed according to the observed sequence preferences in the oxidized Jurkat proteome, we discovered that the substrate specificity of the cellular methionine sulfoxide reductases is a major determinant for the steady-state of methionine oxidation. This was supported by a structural modeling of the MsrA catalytic center. Finally, we applied our method onto a serum proteome from a mouse sepsis model and identified 35 in vivo methionine oxidation events in 27 different proteins.

Collaboration


Dive into the Frederic Rousseau's collaboration.

Top Co-Authors

Avatar

Joost Schymkowitz

Vrije Universiteit Brussel

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joost Van Durme

Vrije Universiteit Brussel

View shared research outputs
Top Co-Authors

Avatar

Hannah Wilkinson

Vrije Universiteit Brussel

View shared research outputs
Top Co-Authors

Avatar

Bart De Strooper

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Inna Kuperstein

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Luis Serrano

Vrije Universiteit Brussel

View shared research outputs
Top Co-Authors

Avatar

Jef Rozenski

Rega Institute for Medical Research

View shared research outputs
Top Co-Authors

Avatar

Luis Serrano

Vrije Universiteit Brussel

View shared research outputs
Researchain Logo
Decentralizing Knowledge